25-Hydroxyvitamin D, Dementia, and Cerebrovascular Pathology in Elders Receiving Home Services

Annweiler, Cédric; Gall, D. Le; Fantino, Bruno; Beauchet, O.; Tucker, Katherine L.; Buell, J. S.

doi:10.1212/wnl.0b013e3181e00ddb

Cited by 14 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the brain level, by its action on different neurotransmitters and several growth factors, low serum 25OHD has been associated with low global cognitive function 30,[32][33][34][35] that was likely explained by hypovitaminosis D-induced executive dysfunction and processing speed impairment. 14,32 Previous studies have highlighted the importance of the executive function for gait control 36,37 and have suggested that STV could be a suitable parameter to assess the executive component of gait control.…”

Section: Resultsmentioning

confidence: 99%

Biology of gait control

Beauchet¹,

Annweiler²,

Verghese³

et al. 2011

Neurology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Biology of gait control

Beauchet¹,

Annweiler²,

Verghese³

et al. 2011

Neurology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Second, vitamin D belongs a complex biological system, and its insufficiency causes an elevation of serum parathormone [109]. Patients with primary hyperparathyroidism usually exhibit cognitive disorders [109,110], that could be reversed after parathyroidectomy [110].…”

Section: Vitamin D and Nervous Systemmentioning

confidence: 99%

“…Patients with primary hyperparathyroidism usually exhibit cognitive disorders [109,110], that could be reversed after parathyroidectomy [110]. Moreover, in the Helsinki Ageing Study, high parathormone concentrations indicated an independent 2-fold risk for a five-year cognitive decline [111].…”

Section: Vitamin D and Nervous Systemmentioning

confidence: 99%

Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects

Annweiler

Montero‐Odasso

Schott

et al. 2010

J NeuroEngineering Rehabil

117

View full text Add to dashboard Cite

Preventing falls and fall-related fractures in the elderly is an objective yet to be reached. There is increasing evidence that a supplementation of vitamin D and/or of calcium may reduce the fall and fracture rates. A vitamin D-calcium supplement appears to have a high potential due to its simple application and its low cost. However, published studies have shown conflicting results as some studies failed to show any effect, while others reported a significant decrease of falls and fractures. Through a 15-year literature overview, and after a brief reminder on mechanism of falls in older adults, we reported evidences for a vitamin D action on postural adaptations - i.e., muscles and central nervous system - which may explain the decreased fall and bone fracture rates and we underlined the reasons for differences and controversies between published data. Vitamin D supplementation should thus be integrated into primary and secondary fall prevention strategies in older adults.

show abstract

“…This sample size has also adequate power (i.e., 90%) to detect a smaller difference in ADAS-cog score (i.e., 2 points). The sample size calculation also assumes accounting for up to 12 covariables anticipating multivariate analyses, including the change in comorbid conditions possibly due to vitamin D supplementation [51] with subsequent indirect cognitive benefits (using the Cumulative Illness Rating Scale for Geriatrics [CIRS-G] score) [52], the education level [1], the season tested [16], and the serum concentrations of parathyroid hormone (PTH) and calcium [53]. …”

Section: Methodsmentioning

confidence: 99%

Alzheimer's disease - input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial

Annweiler

Fantino

Parot-Schinkel

et al. 2011

Trials

View full text Add to dashboard Cite

BackgroundCurrent treatments for Alzheimer's disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD. Future possibilities of care rely on multi-target drugs therapies that address simultaneously several pathophysiological processes leading to neurodegeneration. We hypothesized that the combination of memantine with vitamin D could be neuroprotective in ADRD, thereby limiting neuronal loss and cognitive decline. The aim of this trial is to compare the effect after 24 weeks of the oral intake of vitamin D3 (cholecalciferol) with the effect of a placebo on the change of cognitive performance in patients suffering from moderate ADRD and receiving memantine.MethodsThe AD-IDEA Trial is a unicentre, double-blind, randomized, placebo-controlled, intent-to-treat, superiority trial. Patients aged 60 years and older presenting with moderate ADRD (i.e., Mini-Mental State Examination [MMSE] score between 10-20), hypovitaminosis D (i.e., serum 25-hydroxyvitamin D [25OHD] < 30 ng/mL), normocalcemia (i.e., serum calcium < 2.65 mmol/L) and receiving no antidementia treatment at time of inclusion are being recruited. All participants receive memantine 20 mg once daily -titrated in 5 mg increments over 4 weeks- and each one is randomized to one of the two treatment options: either cholecalciferol (one 100,000 IU drinking vial every 4 weeks) or placebo (administered at the same pace). One hundred and twenty participants are being recruited and treatment continues for 24 weeks. Primary outcome measure is change in cognitive performance using Alzheimer's Disease Assessment Scale-cognition score. Secondary outcomes are changes in other cognitive scores (MMSE, Frontal Assessment Battery, Trail Making Test parts A and B), change in functional performance (Activities of Daily Living scale, and 4-item Instrumental Activities of Daily Living scale), posture and gait (Timed Up & Go, Five Time Sit-to-Stand, spatio-temporal analysis of walking), as well as the between-groups comparison of compliance to treatment and tolerance. These outcomes are assessed at baseline, 12 and 24 weeks, together with the serum concentrations of 25OHD, calcium and parathyroid hormone.DiscussionThe combination of memantine plus vitamin D may represent a new multi-target therapeutic class for the treatment of ADRD. The AD-IDEA Trial seeks to provide evidence on its efficacy in limiting cognitive and functional declines in ADRD.Trial RegistrationClinicalTrials.gov number, NCT01409694

show abstract

25-Hydroxyvitamin D, Dementia, and Cerebrovascular Pathology in Elders Receiving Home Services

Cited by 14 publications

References 29 publications

Biology of gait control

Biology of gait control

Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects

Alzheimer's disease - input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial

Contact Info

Product

Resources

About